Texas ChE Professor Jennifer Maynard and her research team have engineered “antibody-like” T cell receptors that can specifically stick to cells infected with cytomegalovirus, or CMV, a virus that causes lifelong infection in more than half of all adults by age 40. These receptors represent a new potential treatment option, could aid the development of … Read the rest »
Posts Tagged ‘vaccines’
“Antibody-like” T Cell Receptors May Be New Potential Treatment for Cytomegalovirus (#CMV) and Brain Tumors
Ben Wendel (Georgiou Group)
A System Immunology Approach to the Development of Natural Immunity to Malaria
Ben’s research explores the progression of the immune system with age … Read the rest »
South by Southwest (SXSW) Interactive is hosting inventors, thought leaders and entrepreneurs at the festival’s UT Village Sunday, March 15 from 9:30 a.m.-6 p.m. at the Radisson Hotel & Suites in downtown Austin.
The event is an all-day showcase of innovation and expertise that offers visitors the chance to get a behind-the-scenes look at the … Read the rest »
Associate professor Jennifer Maynard’s research group is working to develop a therapeutic vaccine to treat whooping cough—a highly contagious and dangerous disease that causes an estimated 294,000 deaths annually worldwide, primarily among young, unvaccinated children. Whooping cough is on the rise in the United States, and in Texas cases have increased 79 percent in … Read the rest »
The department is pleased to announce top presenters for this year’s Graduate Student Seminar Series, as voted by attending first-year and third-year Ph.D. students:
Jackson Stolle (Korgel Lab)
Photonic Curing of CuInSe2 Nanocrystals for Inexpensive Solar Cells
Jackson’s research uses semiconductor nanocrystal “solar inks” and low-temperature processing to fabricate inexpensive, highly-efficient … Read the rest »
Associate Professor Jennifer Maynard, the Laurence E. McMakin, Jr. Centennial Faculty Fellow, has teamed up with biotech company Synthetic Biologics, Inc. to develop a monoclonal antibody (mAb) therapy for the treatment of pertussis, commonly known as whooping cough.
Whooping cough causes an estimated 294,000 deaths annually worldwide, primarily among young, unvaccinated children. Recent reports … Read the rest »
Professor George Georgiou is leading a team of researchers that recently received a $6.5 million grant from the U.S. Department of Defense and the Defense Threat Reduction Agency to accelerate the evaluation and development of new vaccines for emerging health threats.